VLA 0.00% $1.75 viralytics limited

awarded fda orphan drug status for melanoma

  1. 38 Posts.
    A very detailed report issued by Viriathus Research has just been posted on VLA's website.

    Extremely interesting as this report provides very in-depth information on all aspects of VLA's research ranging from the market value for cancer treatment being a multi-billion dollar industry with cancer being the second highest cause of death with initial treatment costs just in the USA in excess of $6.7 billion to the company now reviewing its toxicology results with the USA FDA.

    They have already secured a GMP-compliant manufacturer in the USA for their lead therapy cavatak.

    With this high degree of uncertainty in the market's traditional areas for investing, biotech stocks are now once again gaining acceptance, especially ones that are operating as lean and with so much promise as viralytics.

    The report is well worth a read.
 
arrow-down-2 Created with Sketch. arrow-down-2 Created with Sketch.